Financial Survey: Cellectis (NASDAQ:CLLS) versus Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ:PBYI) and Cellectis (NASDAQ:CLLS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Institutional and Insider Ownership

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Puma Biotechnology and Cellectis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Cellectis	-102.34%	-94.19%	-21.34%

Valuation and Earnings

This table compares Puma Biotechnology and Cellectis”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40 million	2.36	$31.11 million	$0.52	20.08
Cellectis	$79.59 million	1.36	-$67.59 million	($0.65)	-1.66

Puma Biotechnology has higher revenue and earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Puma Biotechnology has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3, meaning that its share price is 200% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Puma Biotechnology and Cellectis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0	1	1	0	2.50
Cellectis	2	2	2	1	2.29

Puma Biotechnology currently has a consensus price target of $6.00, suggesting a potential downside of 42.53%. Cellectis has a consensus price target of $5.46, suggesting a potential upside of 405.56%. Given Cellectis’ higher possible upside, analysts plainly believe Cellectis is more favorable than Puma Biotechnology.

Summary

Puma Biotechnology beats Cellectis on 10 of the 15 factors compared between the two stocks.

About Puma Biotechnology

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.